IMMUNOGENICITY AND EFFICACY OF A NOVEL CANDIDATE VACCINE FOR AIDS

一种新型艾滋病候选疫苗的免疫原性和功效

• 批准号: 8172662
• 负责人: Krishna K Murthy
• 金额: $ 1.6万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172662
• 关键词: AIDS Vaccines; Acquired Immunodeficiency Syndrome; Antibodies; CD8B1 gene; Computer Retrieval of Information on Scientific Projects Database; Development; Disease Progression; Dose; Epidemic; Funding; Genetic Transcription; Grant; HIV; Human; Immune system; Infection prevention; Institution; Leukocytes; Macaca; Modeling; Monkeys; Peptides; Persons; Proteins; Reporting; Research; Research Personnel; Resources; Source; System; T-Lymphocyte; Trans-Activators; United States National Institutes of Health; Vaccinated; Vaccines; Virus; Virus Replication; immunogenicity; novel; tat Protein; vaccine candidate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main objective is to determine the immunogenicity and efficacy of a novel candidate vaccine for AIDS in the macaque model. The vaccine is formulated with a novel synthetic multi-peptide conjugate (MPC) system that represents one of the major proteins of HIV known as Tat (trans activator of transcription). Tat protein has an important function in replication of the virus. Therefore, we plan to vaccinate monkeys with a synthetic MPC Tat vaccine to stimulate the monkey's immune system to produce virus specific proteins (antibodies), and white blood cells (CD4+ and CD8+ T cells). The vaccinated and unvaccinated control monkeys will be challenged with a known dose of infectious virus to determine whether the vaccine will prevent infection and or disease progression. The first AIDS cases were reported two decades ago, and WHO has recently released a report indicating that approximately 40 million persons are infected with HIV worldwide. As yet, there is no effective vaccine for prevention of infection and the epidemic continues to spread. If the proposed study is successful, it is likely to provide important information toward development of an effective vaccine for human application.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 主要目的是确定新型候选疫苗在猕猴模型中的免疫原性和功效。该疫苗用一种新型的合成多肽结合物（MPC）系统配制，该系统代表了HIV的主要蛋白质之一，称为TAT（转录的反式激活剂）。 TAT蛋白在复制病毒方面具有重要功能。因此，我们计划用合成的MPC TAT疫苗接种猴子，以刺激猴子的免疫系统产生病毒特异性蛋白（抗体）和白细胞（CD4+和CD8+ T细胞）。接种疫苗和未接种的对照猴子将受到已知剂量的传染性病毒的挑战，以确定该疫苗是否会防止感染和 /或疾病进展。急救案件是二十年前的报道，最近发布了一份报告，表明大约有4000万人感染了全世界的艾滋病毒。到目前为止，还没有有效的疫苗预防感染，并且流行病继续扩散。如果拟议的研究成功，则很可能为开发有效的人类应用疫苗提供重要信息。